Prognostic value of procalcitonin in patients after elective cardiac surgery: a prospective cohort study

Matthias Klingele, Hagen Bomberg, Simone Schuster, Hans-Joachim Schäfers, Heinrich Volker Groesdonk, Matthias Klingele, Hagen Bomberg, Simone Schuster, Hans-Joachim Schäfers, Heinrich Volker Groesdonk

Abstract

Background: Procalcitonin (PCT) is a well-known prognostic marker after elective cardiac surgery. However, the impact of elevated PCT in patients with an initially uneventful postoperative course is still unclear. The aim of this study was to evaluate PCT levels as a prognostic tool for delayed complications after elective cardiac surgery.

Methods: A prospective study was performed in 751 patients with an apparently uneventful postoperative course within the first 24 h after elective cardiac surgery. Serum PCT concentration was taken the morning after surgery. All patients were screened for the occurrence of delayed complications. Delayed complications were defined by in-hospital death, intensive care unit readmission, or prolonged length of hospital stay (>12 days). Odds ratios (OR) [with 95% confidence interval (CI)] were calculated by logistic regression analyses and adjusted for confounders. Predictive capacity of PCT for delayed complications was calculated by ROC analyses. The cutoff value of PCT was derived from the Youden Index calculation.

Results: Among 751 patients with an initially uneventful postoperative course, 117 patients developed delayed complications. Serum PCT levels the first postoperative day were significantly higher in these 117 patients (8.9 ng/ml) compared to the remaining 634 (0.9 ng/ml; p < 0.001). ROC analyses showed that PCT had a high accuracy to predict delayed complications (optimal cutoff value of 2.95 ng/ml, AUC of 0.90, sensitivity 73% and specificity 97%). Patients with PCT levels above 2.95 ng/ml the first postoperative day had a highly increased risk of delayed complications (adjusted OR, 110.2; 95% CI 51.5-235.5; p < 0.001).

Conclusions: A single measurement of PCT seems to be a useful tool to identify patients at risk of delayed complications despite an initially uneventful postoperative course.

Keywords: Cardiac surgery; Delayed complications; Procalcitonin; Risk factor.

Figures

Fig. 1
Fig. 1
Flowchart
Fig. 2
Fig. 2
Postoperative serum levels of procalcitonin and ROC curve analysis

References

    1. Adamik B, Kubler-Kielb J, Golebiowska B, Gamian A, Kubler A. Effect of sepsis and cardiac surgery with cardiopulmonary bypass on plasma level of nitric oxide metabolites, neopterin, and procalcitonin: correlation with mortality and postoperative complications. Intensive Care Med. 2000;26(9):1259–1267. doi: 10.1007/s001340000610.
    1. Beghetti M, Rimensberger PC, Kalangos A, Habre W, Gervaix A. Kinetics of procalcitonin, interleukin 6 and C-reactive protein after cardiopulmonary-bypass in children. Cardiol Young. 2003;13(2):161–167. doi: 10.1017/S1047951103000301.
    1. Dorge H, Schondube FA, Dorge P, Seipelt R, Voss M, Messmer BJ. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. Thorac Cardiovasc Surg. 2003;51(6):322–326. doi: 10.1055/s-2003-45425.
    1. Lecharny JB, Khater D, Bronchard R, Philip I, Durand G, Desmonts JM, Dehoux M. Hyperprocalcitonemia in patients with perioperative myocardial infarction after cardiac surgery. Crit Care Med. 2001;29(2):323–325. doi: 10.1097/00003246-200102000-00019.
    1. Meisner M, Rauschmayer C, Schmidt J, Feyrer R, Cesnjevar R, Bredle D, Tschaikowsky K. Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications. Intensive Care Med. 2002;28(8):1094–1102. doi: 10.1007/s00134-002-1392-5.
    1. Fritz HG, Brandes H, Bredle DL, Bitterlich A, Vollandt R, Specht M, Franke UF, Wahlers T, Meier-Hellmann A. Post-operative hypoalbuminaemia and procalcitonin elevation for prediction of outcome in cardiopulmonary bypass surgery. Acta Anaesthesiol Scand. 2003;47(10):1276–1283. doi: 10.1046/j.1399-6576.2003.00239.x.
    1. Loebe M, Locziewski S, Brunkhorst FM, Harke C, Hetzer R. Procalcitonin in patients undergoing cardiopulmonary bypass in open heart surgery-first results of the Procalcitonin in Heart Surgery study (ProHearts) Intensive Care Med. 2000;26(Suppl 2):S193–S198.
    1. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49(Suppl 1):S57–S61.
    1. Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8(6):307–321. doi: 10.4254/wjh.v8.i6.307.
    1. Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404.
    1. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–518. doi: 10.1016/0140-6736(93)90277-N.
    1. Gogos CA, Skoutelis A, Lekkou A, Drosou E, Starakis I, Marangos MN, Bassaris HP. Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother. 2004;48(8):2793–2798. doi: 10.1128/AAC.48.8.2793-2798.2004.
    1. Adrie C, Laurent I, Monchi M, Cariou A, Dhainaou JF, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit Care. 2004;10(3):208–212. doi: 10.1097/01.ccx.0000126090.06275.fe.
    1. Aouifi A, Piriou V, Blanc P, Bouvier H, Bastien O, Chiari P, Rousson R, Evans R, Lehot JJ. Effect of cardiopulmonary bypass on serum procalcitonin and C-reactive protein concentrations. Br J Anaesth. 1999;83(4):602–607. doi: 10.1093/bja/83.4.602.
    1. Macrina F, Tritapepe L, Pompei F, Sciangula A, Evangelista E, Toscano F, Criniti A, Brancaccio G, Puddu PE. Procalcitonin is useful whereas C-reactive protein is not, to predict complications following coronary artery bypass surgery. Perfusion. 2005;20(3):169–175. doi: 10.1191/0267659105pf800oa.
    1. Benetis R, Sirvinskas E, Kumpaitiene B, Kinduris S. A case-control study of readmission to the intensive care unit after cardiac surgery. Med Sci Monit. 2013;19:148–152. doi: 10.12659/MSM.883814.
    1. Kiessling AH, Huneke P, Reyher C, Bingold T, Zierer A, Moritz A. Risk factor analysis for fast track protocol failure. J Cardiothorac Surg. 2013;8:47. doi: 10.1186/1749-8090-8-47.
    1. Lipinska-Gediga M, Mierzchala-Pasierb M, Durek G. Procalcitonin kinetics–prognostic and diagnostic significance in septic patients. Arch Med Sci. 2016;12(1):112–119. doi: 10.5114/aoms.2016.57587.
    1. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury N Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi: 10.1186/cc5713.
    1. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997;112(3):676–692. doi: 10.1378/chest.112.3.676.
    1. Kallel S, Abid M, Jarraya A, Abdenadher M, Mnif E, Frikha I, Ayadi F, Karoui A. Kinetics, diagnostic and prognostic value of procalcitonin after cardiac surgery. Ann Biol Clin (Paris) 2012;70(5):567–580.
    1. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006;34(10):2596–2602. doi: 10.1097/01.CCM.0000239116.01855.61.
    1. Sablotzki A, Dehne MG, Friedrich I, Grond S, Zickmann B, Muhling J, Silber RE, Czeslick EG. Different expression of cytokines in survivors and non-survivors from MODS following cardiovascular surgery. Eur J Med Res. 2003;8(2):71–76.
    1. Adib-Conquy M, Monchi M, Goulenok C, Laurent I, Thuong M, Cavaillon JM, Adrie C. Increased plasma levels of soluble triggering receptor expressed on myeloid cells 1 and procalcitonin after cardiac surgery and cardiac arrest without infection. Shock. 2007;28(4):406–410. doi: 10.1097/shk.0b013e3180488154.
    1. Prat C, Ricart P, Ruyra X, Dominguez J, Morillas J, Blanco S, Tomasa T, Torres T, Camara L, Molinos S, et al. Serum concentrations of procalcitonin after cardiac surgery. J Card Surg. 2008;23(6):627–632. doi: 10.1111/j.1540-8191.2008.00658.x.
    1. Nie X, Wu B, He Y, Huang X, Dai Z, Miao Q, Song H, Luo T, Gao B, Wang L, et al. Serum procalcitonin predicts development of acute kidney injury in patients with suspected infection. Clin Chem Lab Med. 2013;51(8):1655–1661.
    1. Schuetz P, Daniels LB, Kulkarni P, Anker SD, Mueller B. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol. 2016;223:390–397. doi: 10.1016/j.ijcard.2016.08.204.
    1. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011;37(2):384–392. doi: 10.1183/09031936.00035610.
    1. Heredia-Rodriguez M, Bustamante-Munguira J, Fierro I, Lorenzo M, Jorge-Monjas P, Gomez-Sanchez E, Alvarez FJ, Bergese SD, Eiros JM, Bermejo-Martin JF, et al. Procalcitonin cannot be used as a biomarker of infection in heart surgery patients with acute kidney injury. J Crit Care. 2016;33:233–239. doi: 10.1016/j.jcrc.2016.01.015.
    1. Kurtul A, Murat SN, Yarlioglues M, Duran M, Ocek AH, Celik IE, Kilic A, Koseoglu C, Oksuz F, Baris VO. Procalcitonin as an early predictor of contrast-induced acute kidney injury in patients with acute coronary syndromes who underwent percutaneous coronary intervention. Angiology. 2015;66(10):957–963. doi: 10.1177/0003319715572218.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel